Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895577 | 0.71 | — | — | |
| SCHEMBL3069943 | 0.69 | — | — | |
| SCHEMBL1420112 | 0.68 | CYP2B6 (0.42) | CA1CA9STSCYP1A1CYP1A2 | |
| SCHEMBL29804409 | 0.68 | CYP2B6 (0.42) | CA1CA9STSCYP1A1CYP1A2 | |
| SCHEMBL15062465 | 0.68 | CA1 (0.36) | CA1CA9 | |
| SCHEMBL21457851 | 0.68 | — | — | |
| SCHEMBL277112 | 0.68 | CA1 (0.32) | CA1CA9CYP2B6 | |
| SCHEMBL322096 | 0.67 | CYP2B6 (0.41) | CA1CA9STSCYP1A1CYP1A2 | |
| SCHEMBL2119471 | 0.67 | CA1 (0.31) | CA1CA9STS | |
| SCHEMBL2289180 | 0.66 | CYP2B6 (0.43) | CA1CA9STSCYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | claimed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-20180201989-A1 | OXIDANT AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9751821-B1 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9676692-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-2792675-B1 | COMPOUND AND ASYMMETRIC SYNTHESIS REACTION | MICROBIAL CHEM RES FOUND (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-5846991-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| US-5840909-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5817828-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0852584-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| US-5721264-A | EXHIBIT ANTAGONISTIC EFFECT AGAINST ANGIOTENSIN II; USEFUL FOR PREVENTION AND REMEDY OF HYPERTENSION, CONGESTIVE HEARTFAILURE, CHRONIC RENAL INSUFFICIENCY, ALDOSTERONISM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0811629-A1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997011961-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| EP-0693480-A1 | PYRAZOLE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | CA1 3993/4885CA9 3025/4885STS 1920/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | CA1 3993/4885CA9 3025/4885STS 1920/4885 |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | CA1 343/4885CA9 2960/4885STS 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.